Jane Street Group LLC Sells 33,439 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Jane Street Group LLC lowered its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 50.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,929 shares of the company’s stock after selling 33,439 shares during the period. Jane Street Group LLC’s holdings in Trevi Therapeutics were worth $110,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of TRVI. BNP Paribas Financial Markets raised its stake in Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after purchasing an additional 6,764 shares in the last quarter. Hsbc Holdings PLC bought a new position in shares of Trevi Therapeutics in the 2nd quarter worth $61,000. Intech Investment Management LLC purchased a new stake in shares of Trevi Therapeutics during the 3rd quarter valued at $63,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Trevi Therapeutics by 87.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after acquiring an additional 11,450 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in Trevi Therapeutics in the third quarter worth $78,000. Institutional investors own 95.76% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on TRVI. B. Riley restated a “buy” rating and set a $6.00 price target on shares of Trevi Therapeutics in a research report on Monday, October 7th. D. Boral Capital reissued a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a report on Wednesday, January 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research note on Thursday, December 12th. Finally, HC Wainwright lifted their price target on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a research note on Thursday, December 12th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $9.31.

Trevi Therapeutics Stock Performance

NASDAQ:TRVI opened at $3.93 on Wednesday. Trevi Therapeutics, Inc. has a fifty-two week low of $1.27 and a fifty-two week high of $4.68. The firm has a market cap of $302.08 million, a PE ratio of -8.93 and a beta of 0.87. The business has a 50 day moving average price of $3.45 and a 200-day moving average price of $3.16.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter last year, the firm earned ($0.08) EPS. Research analysts predict that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.